Log in

Relevant bibliographies by topics / Intratumoral dispersion / Journal articles

To see the other types of publications on this topic, follow the link: Intratumoral dispersion.

Journal articles on the topic 'Intratumoral dispersion'

Author: Grafiati

Published: 4 June 2021

Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 16 journal articles for your research on the topic 'Intratumoral dispersion.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Latifa, Mohammedi, Djillali Doula Fatima, Mesli Farida, and Senhadji Rachid. "Intra-tumoral distribution of Ki-67 and Cyclin D1 in ER+ mammary carcinoma: quantitative evaluation." African Health Sciences 21, no. 1 (2021): 41–6. http://dx.doi.org/10.4314/ahs.v21i1.7.

Full text

Abstract:

Background: In spite of the strong evidence demonstrating the role of overexpression of Ki-67 and Cyclin D1 markers in breast carcinomas, clinical and pathological data remain to be discussed. This can be explained partly by intratumor het- erogeneity. Objectives: To define the prevalence and clinical significance of Ki-67 and Cyclin D1 overexpression in primary breast tumors ER positive, while highlighting the existence of intratumor heterogeneity in this type of cancer. Materials and methods: 51 ER positive breast cancer tumors were used to evaluate the intratumoral distribution

APA, Harvard, Vancouver, ISO, and other styles

2

Sharifi‐Salamatian, Vénus, Anne de Roquancourt, and Jean Paul Rigaut. "Breast Carcinoma, Intratumour Heterogeneity and Histological Grading, Using Geostatistics." Analytical Cellular Pathology 20, no. 2-3 (2000): 83–91. http://dx.doi.org/10.1155/2000/164360.

Full text

Abstract:

Tumour progression is currently believed to result from genetic instability. Chromosomal patterns specific of a type of cancer are frequent even though phenotypic spatial heterogeneity is omnipresent. The latter is the usual cause of histological grading imprecision, a well documented problem, without any fully satisfactory solution up to now. The present article addresses this problem in breast carcinoma. The assessment of a genetic marker for human tumours requires quantifiable measures of intratumoral heterogeneity. If any invariance paradigm representing a stochastic or geostatistic functi

APA, Harvard, Vancouver, ISO, and other styles

3

Galling, Nele, Dennis Kobelt, Jutta Aumann та ін. "Intratumoral Dispersion, Retention, Systemic Biodistribution, and Clearance of a Small-Size Tumor Necrosis Factor-α-Expressing MIDGE Vector After Nonviralin VivoJet-Injection Gene Transfer". Human Gene Therapy Methods 23, № 4 (2012): 264–70. http://dx.doi.org/10.1089/hgtb.2012.064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Fordham, Austin-John, Caitlin-Craft Hacherl, Neal Patel, et al. "Differentiating Glioblastomas from Solitary Brain Metastases: An Update on the Current Literature of Advanced Imaging Modalities." Cancers 13, no. 12 (2021): 2960. http://dx.doi.org/10.3390/cancers13122960.

Full text

Abstract:

Differentiating between glioblastomas and solitary brain metastases proves to be a challenging diagnosis for neuroradiologists, as both present with imaging patterns consisting of peritumoral hyperintensities with similar intratumoral texture on traditional magnetic resonance imaging sequences. Early diagnosis is paramount, as each pathology has completely different methods of clinical assessment. In the past decade, recent developments in advanced imaging modalities enabled providers to acquire a more accurate diagnosis earlier in the patient’s clinical assessment, thus optimizing clinical ou

APA, Harvard, Vancouver, ISO, and other styles

5

Bender, Lewis H., Franco Abbate, and Ian B. Walters. "Intratumoral Administration of a Novel Cytotoxic Formulation with Strong Tissue Dispersive Properties Regresses Tumor Growth and Elicits Systemic Adaptive Immunity in In Vivo Models." International Journal of Molecular Sciences 21, no. 12 (2020): 4493. http://dx.doi.org/10.3390/ijms21124493.

Full text

Abstract:

The recent development of immune-based therapies has improved the outcome for cancer patients; however, adjuvant therapies remain an important line of treatment for several cancer types. To maximize efficacy, checkpoint inhibitors are often combined with cytotoxic agents. While this approach often leads to increased tumor regression, higher off target toxicity often results in certain patients. This report describes a novel formulation comprising a unique amphiphilic molecule, 8-((2-hydroxybenzoyl)amino)octanoate (SHAO), that non-covalently interacts with payloads to increase drug dispersion a

APA, Harvard, Vancouver, ISO, and other styles

6

Binder, Moritz, Sandeep Potluri, Ryan M. Carr, et al. "ASXL1-Mutant Chronic Myelomonocytic Leukemia Is Associated with Increased Intratumoral Heterogeneity and Single-Cell Chromatin Co-Accessibility." Blood 136, Supplement 1 (2020): 27–28. http://dx.doi.org/10.1182/blood-2020-134977.

Full text

Abstract:

Introduction: Additional Sex Combs-Like 1 (ASXL1) is a chromatin modifier frequently affected by truncating mutations in myeloid malignancies. In chronic myelomonocytic leukemia (CMML), truncating ASXL1 mutations are associated with the overexpression of leukemogenic driver genes, however the molecular mechanisms underlying this transcriptional activation remain controversial. We performed single-cell chromatin accessibility studies of ASXL1-mutant (MT) and -wildtype (WT) CMML to identify cis-regulatory elements (CREs) such as distal enhancer elements that may explain the observed transcriptio

APA, Harvard, Vancouver, ISO, and other styles

7

Le Tourneau, Christophe, Valentin Calugaru, Edith Borcoman, et al. "Phase I trial of hafnium oxide nanoparticles activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients." Journal of Clinical Oncology 38, no. 15_suppl (2020): 6573. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.6573.

Full text

Abstract:

6573 Background: The standard of care non-surgical approach for locally advanced head and neck squamous cell carcinoma (LA HNSCC) patients (pts) is concurrent chemoradiation with high dose cisplatin or cetuximab in case of contra-indication. Older age is a contra-indication to cisplatin, and cetuximab might not improve survival in older pts. It is therefore urgently needed to develop new treatment options for elderly pts with LA HNSCC. NBTXR3 are hafnium oxide nanoparticles that can enhance the efficacy of radiotherapy (RT) by increasing locally the deposited dose. In this phase I clinical tri

APA, Harvard, Vancouver, ISO, and other styles

8

Cunha-Filho, Marcilio S. S., Carmen Alvarez-Lorenzo, Ramón Martínez-Pacheco та Mariana Landin. "Temperature-Sensitive Gels for Intratumoral Delivery ofβ-Lapachone: Effect of Cyclodextrins and Ethanol". Scientific World Journal 2012 (2012): 1–8. http://dx.doi.org/10.1100/2012/126723.

Full text

Abstract:

This work evaluated the potential of Pluronics (varieties F127 and P123) in combination with solubilizing agents to be used as syringeablein situgelling depots of intratumoralβ-lapachone (βLAP). Pluronic dispersions prepared at various concentrations in the absence and the presence of ethanol and randomly methylatedβ-cyclodextrin (RMβCD) were characterized regarding their rheological properties, drug solubilization capacity, andin vitrorelease. Pluronic F127 (18–23%) formulations combined high ability to solubilizeβLAP (enhancement solubility factor up to 50), adequate gel temperature range (o

APA, Harvard, Vancouver, ISO, and other styles

9

El-Khoueiry, Anthony B., Jacob Stephen Thomas, Diana L. Hanna, et al. "Safety profile of INT230-6, a novel intratumoral (IT) formulation, during injections into a variety of refractory deep and superficial tumors with evidence of tumor regression and immune activation." Journal of Clinical Oncology 37, no. 15_suppl (2019): 2602. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.2602.

Full text

Abstract:

2602 Background: INT230-6 is comprised of cisplatin (CIS), vinblastine (VIN) and an amphiphilic penetration enhancer which facilitates dispersion throughout tumors and diffusion into cancer cells. In preclinical experiments, INT230-6 led to necrosis and recruitment of immune cells with high rates of complete responses of injected and bystander tumors. This abstract highlights the safety and early pharmacodynamic activity of this approach. Methods: Patients with solid tumors that progressed on all standard treatments were enrolled. Dose escalation occurred by increasing number of tumors injecte

APA, Harvard, Vancouver, ISO, and other styles

10

El-Khoueiry, Anthony, Jacob Thomas, Anthony Olszanski, et al. "411 Novel intratumoral agent, INT230–6 induces cancer cell death, increases tumor infiltrates and results in durable benefit alone or in combination with pembrolizumab in refractory patients." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A436. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0411.

Full text

Abstract:

BackgroundINT230-6 is a novel formulation of cisplatin and vinblastine with an amphiphilic cell penetration enhancer that has been shown to enhance dispersion of the drug throughout tumors and allow diffusion into cells when given intratumorally. In preclinical models, INT230-6 has resulted in cell death, dendritic cell influx, antigen presentation and T-cell engagement with strong synergy when combined with checkpoint inhibitorsMethodsThis phase 1/2 study evaluated Q2week injections of INT230-6 x 5 dosed by tumor volume alone or with 200 mg pembrolizumab IV Q3 weeks. Eligble patients had any

APA, Harvard, Vancouver, ISO, and other styles

11

Chung, Stephen S., Priyanka Vijay, Diana L. Stern, et al. "Analysis of Myelodysplastic Syndrome Stem Cells at Single Cell Resolution during DNA Methyltransferase Inhibitor Therapy." Blood 126, no. 23 (2015): 4101. http://dx.doi.org/10.1182/blood.v126.23.4101.4101.

Full text

Abstract:

Abstract The myelodysplastic syndromes (MDS) arise in and are maintained by hematopoietic stem cells (HSCs). Serial sampling of patients treated with DNA methyltransferase inhibitors (DNMTIs) and lenalidomide has demonstrated that disease HSCs (MDS HSCs) persist at significant levels even in patients achieving complete clinical and cytogenetic responses. As MDS HSCs are the functional unit of clonal selection both during therapy and subsequent disease progression, we hypothesized that the molecular heterogeneity of MDS HSCs may underlie therapeutic resistance. We therefore sought to perform si

APA, Harvard, Vancouver, ISO, and other styles

12

Thomas, Jacob Stephen, Anthony B. El-Khoueiry, Ian B. Walters, et al. "Pharmacodynamic, safety, and efficacy results of a phase I/II trial of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab (PEM) (Keynote A10) in patients with advanced solid tumors." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3016. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3016.

Full text

Abstract:

3016 Background: INT230-6 is comprised of cisplatin (CIS), vinblastine (VIN) and an amphiphilic penetration enhancer which facilitates dispersion throughout tumors and diffusion into cancer cells when given IT. Preclinical experiments show strong synergy with a PD1 antibody. Methods: Solid tumors pts that progressed on standard treatment were enrolled. INT230-6 dose was set by tumor volume, injected Q2weeks x 5. Escalation occurred by increasing number of tumors injected, loading per tumor, and total dose. In another arm, PEM (200mg IV Q3weeks) was combined with INT230-6. Patients were monitor

APA, Harvard, Vancouver, ISO, and other styles

13

El-Khoueiry, Anthony B., Jacob Stephen Thomas, Anthony J. Olszanski, et al. "A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy." Journal of Clinical Oncology 39, no. 15_suppl (2021): 2592. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.2592.

Full text

Abstract:

2592 Background: Study IT-01 (KEYNOTE-A10) evaluates INT230-6, a novel formulation of cisplatin (CIS) and vinblastine (VIN) with an amphiphilic cell penetration enhancer designed for intratumoral (IT) administration, alone or in combination with pembrolizumab (PEM), an antibody to PD-1. INT230-6 dosing is set by a tumor’s volume. In preclinical studies, INT230-6 increases drug dispersion throughout the tumor, allows drug diffusion into cancer cells and recruits dendritic, CD4 and CD8 T cells. The addition of PEM has been shown to improve these responses in models. Phase 1 data indicated INT230

APA, Harvard, Vancouver, ISO, and other styles

14

Brunelli, Matteo, Sara Elena Rebuzzi, Valerio Gaetano Vellone, et al. "Fusion 3D gross sampling method to overcome heterogeneity in clear cell renal cell carcinoma (ccRCC) and grading angiogenic versus immune signatures." Journal of Clinical Oncology 39, no. 15_suppl (2021): e16565-e16565. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e16565.

Full text

Abstract:

e16565 Background: Grading tissue signatures in ccRCC is a potential tool to improve patients’ selection for anti-angiogenic drugs and immunotherapies. After the molecular audit to the TCGA public platforms, we aimed to grade angiogenic and immune signatures in ccRCC using a new 3D next-generation gross sampling method to overcome intratumoral heterogeneity. Methods: 100 consecutive advanced ccRCCs (≥pT3a) were sampled. Paraffin-embedded blocks were obtained after mapping the position of each sample to the whole tumor, to allow the reconstruction of the entire 3D tumor mass ( fusion 3D). Multi

APA, Harvard, Vancouver, ISO, and other styles

15

Kato, Hiroki, Xuhao Huang, Yuichiro Kadonaga, et al. "Intratumoral administration of astatine-211-labeled gold nanoparticle for alpha therapy." Journal of Nanobiotechnology 19, no. 1 (2021). http://dx.doi.org/10.1186/s12951-021-00963-9.

Full text

Abstract:

Abstract Background 211At is a high-energy α-ray emitter with a relatively short half-life and a high cytotoxicity for cancer cells. Its dispersion can be imaged using clinical scanners, and it can be produced in cyclotrons without the use of nuclear fuel material. This study investigated the biodistribution and the antitumor effect of 211At-labeled gold nanoparticles (211At-AuNP) administered intratumorally. Results AuNP with a diameter of 5, 13, 30, or 120 nm that had been modified with poly (ethylene glycol) methyl ether (mPEG) thiol and labeled with 211At (211At-AuNP-S-mPEG) were incubated

APA, Harvard, Vancouver, ISO, and other styles

16

Galling, Nele, Dennis Kobelt, Jutta Aumann та ін. "Intratumoral dispersion, retention, systemic biodistribution and clearance of a small-size TNF-α expressing MIDGE vector following nonviral in vivo jet-injection gene transfer". Human Gene Therapy Methods, 17 жовтня 2012, 121017063203000. http://dx.doi.org/10.1089/hum.2012.064.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!